miR-193a-5p Inhibits Migration and Invasion of Colorectal Cancer Cells Via Targeting Vimentin

Saeed Noorolyai, Behzad Baradaran


Background and Purpose: Colorectal cancer is the third leading cause of cancer death worldwide. MicroRNAs are a group of post-transcription regulators whose expression are altered in various cancers and affect the expression of different genes and contribute to cancer progression. According to studies, the expression of miR-193a-5p in some cancers, including colorectal cancer, is reduced. But so far, the main effects and mechanisms of miR-193a-5p in colorectal cancer are ambiguous and unknown. The purpose of this study was to investigate the effects of miR-193a-5p mimic transfection on HT-29 cell line and investigate the expression of vimentin molecule on these cells. Materials and Methods: First, the HT-29 cell line from colorectal cancer was cultured in RPMI-1640 culture media. Then, miR-193a-5p was transfected with Jet-PEI reagent and using the qRT-PCR technique, the expression of miR-193a-5p and vimentin gene was evaluated in miR-193a-5p transfected HT-29 cells and control group. Statistical analyzes were performed using GraphPad Prism 6 statistical software. Results: In this study, the simultaneous effect of miR-193a-5p mimic on HT-29 cells was investigated. Expression levels of miR-193a-5p was increased after transfection, and then, vimentin expression was altered, which was evaluated by using qRT-PCR. Conclusion: The results of this study revealed that miR-193a-5p may act as a tumor-suppressor by affecting the molecules such as vimentin. This microRNA has an important role in tumor metastasis. Therefore, it may be suggested as a potential therapeutic target in the treatment of colorectal cancer.


Colorectal Cancer, HT-29, miR193a, Vimentin

Full Text:



Blanco-Calvo, M., et al., Colorectal cancer classification and cell heterogeneity: a systems oncology approach. International journal of molecular sciences, 2015. 16(6): p. 13610-13632.

Haggar, F.A. and R.P. Boushey, Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clinics in colon and rectal surgery, 2009. 22(4): p. 191.

Arnold, M., et al., Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017. 66(4): p. 683-691.

Leivonen, S.-K., et al., High‐throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Molecular oncology, 2014. 8(1): p. 93-104.

Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. cell, 2011. 144(5): p. 646-674.

Parsons, D.W., et al., Colorectal cancer: mutations in a signalling pathway. Nature, 2005. 436(7052): p. 792.

Laššuthová, P., et al., Clinical, in silico, and experimental evidence for pathogenicity of two novel splice site mutations in the SH3TC2 gene. Journal of neurogenetics, 2012. 26(3-4): p. 413-420.

Josien, C. and F. René, The role of small noncoding RNAs in genome stability and chromatineorganization. J Cell Sci, 2010. 123: p. 1825-39.

Baghbani, E., et al., PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b. Advanced Pharmaceutical Bulletin, 2018. 8(2): p. 277.

Garzon, R., G.A. Calin, and C.M. Croce, MicroRNAs in cancer. Annual review of medicine, 2009. 60: p. 167-179.

Lee, R.C., R.L. Feinbaum, and V. Ambros, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. cell, 1993. 75(5): p. 843-854.

Hosseinahli, N., et al., Treating cancer with microRNA replacement therapy: A literature review. Journal of cellular physiology, 2018. 233(8): p. 5574-5588.

Wightman, B., I. Ha, and G. Ruvkun, Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 1993. 75(5): p. 855-862.

Chen, X., et al., MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer research, 2010: p. 0008-5472. CAN-09-3718.

Huppi, K., et al. MicroRNAs and genomic instability. in Seminars in cancer biology. 2007. Elsevier.

Aslam, M.I., et al., MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. Journal of translational medicine, 2012. 10(1): p. 128.

Orellana, E.A. and A.L. Kasinski, MicroRNAs in cancer: a historical perspective on the path from discovery to therapy. Cancers, 2015. 7(3): p. 1388-1405.

Calin, G.A., et al., Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 2002. 99(24): p. 15524-15529.

Bouchie, A., First microRNA mimic enters clinic. 2013, Nature Publishing Group.

Gougelet, A., et al., Micro‐RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. International journal of cancer, 2011. 129(3): p. 680-690.

Wuchty, S., et al., Involvement of microRNA families in cancer. Nucleic acids research, 2012. 40(17): p. 8219-8226.

Gambari, R., et al., Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology. International journal of oncology, 2016. 49(1): p. 5-32.

Esquela-Kerscher, A. and F.J. Slack, Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer, 2006. 6(4): p. 259.

Bonfrate, L., et al., MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. Journal of Gastrointestinal & Liver Diseases, 2013. 22(3).

Iio, A., et al., Identification of non-coding RNAs embracing microRNA-143/145 cluster. Molecular cancer, 2010. 9(1): p. 136.

Henry, J.C., A.C.P. Azevedo-Pouly, and T.D. Schmittgen, MicroRNA replacement therapy for cancer. Pharmaceutical research, 2011. 28(12): p. 3030-3042.

Bader, A.G., miR-34–a microRNA replacement therapy is headed to the clinic. Frontiers in genetics, 2012. 3: p. 120.

Eriksson, J.E., et al., Introducing intermediate filaments: from discovery to disease. The Journal of clinical investigation, 2009. 119(7): p. 1763-1771.

Toiyama, Y., et al., Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis, 2013. 34(11): p. 2548-57.

Satelli, A. and S. Li, Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and molecular life sciences, 2011. 68(18): p. 3033-3046.

Alfonso, P., et al., Proteomic expression analysis of colorectal cancer by two‐dimensional differential gel electrophoresis. Proteomics, 2005. 5(10): p. 2602-2611.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2019 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine